Fulgent Genetics Q4 Adjusted EPS $0.28 May Not Be Comparable To $(0.29) Estimate, Sales $70.50M Beat $66.32M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fulgent Genetics reported its Q4 adjusted EPS at $0.28, which may not be directly comparable to the estimated $(0.29). The company's sales of $70.50M exceeded the estimated $66.32M.
February 28, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fulgent Genetics reported a Q4 adjusted EPS of $0.28, surpassing the estimated $(0.29), with sales reaching $70.50M, beating the $66.32M estimate.
The positive earnings report, especially the higher-than-expected sales figure, is likely to instill investor confidence and could lead to a short-term uptick in FLGT's stock price. The surpassing of EPS estimates, despite not being directly comparable, further adds to the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100